Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Patents (Class 424/489)
  • Patent number: 11065297
    Abstract: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 20, 2021
    Assignee: MONASH UNIVERSITY
    Inventors: Michelle McIntosh, David Morton, Tomas Sou, Livesey Olerile, Richard Prankerd
  • Patent number: 11058717
    Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 13, 2021
    Assignee: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei Sun
  • Patent number: 11058771
    Abstract: A patch for treating vascular ulcers caused by excessive enzymatic activity may include a substrate configured to span a vascular ulcer as well as a linking material that is disposed relative to the substrate and has an affinity for an enzyme involved in causing the vascular ulcer. A magnetic material may be coupled to the linking material. In some cases, the enzymes involved in causing the vascular ulcer may become coupled to the linking material and thus become coupled to the magnetic material so that that the enzymes can be removed by applying a magnetic field in the proximity of the vascular ulcer. The enzymes may include matrix metalloproteinases.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: July 13, 2021
    Assignee: BOSTON SCIENTIFIC SCIMED, INC.
    Inventor: Matthew Hunt
  • Patent number: 11053422
    Abstract: A chain-reactive, heat-generating microcapsule comprises a first compartment including a first component and a second compartment including a second component. An isolating structure separates the first and second compartments. The isolating structure may rupture when heated above a normal ambient temperature and/or in response to a compressive force. The first component reacts with the second component to produce heat. The microcapsule may further incorporate a blowing agent that responds to heating. In some embodiments, a core within the first compartment comprises a blowing agent material that responds to the heat produced when the first and second components react. The microcapsules can be incorporated into a material comprising a heat-curable resin precursor such that heat generated by the microcapsules can be used to cure the resin precursor.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: July 6, 2021
    Assignee: International Business Machines Corporation
    Inventors: Eric J. Campbell, Sarah K. Czaplewski, Joseph Kuczynski, Timothy J. Tofil
  • Patent number: 11045493
    Abstract: Provided, inter alia, are synthetic melanin nanoparticles (MelNPs) useful for protecting keratinocytes from UV-damage and for treating melanin-defective diseases.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: June 29, 2021
    Assignee: The Regents of the University of California
    Inventors: Nathan C. Gianneschi, Yuran Huang, Yiwen Li
  • Patent number: 11039992
    Abstract: Described herein are compositions that include a saline solution and reactive oxygen species. Specifically, the composition may include a saline solution, reactive oxygen species, an emollient, and a pH modifier. Also provided is a gel composition that includes a rheology agent. Also provided are methods of making and using the compositions.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 22, 2021
    Assignee: REOXYCN, LLC
    Inventor: Kurt Richards
  • Patent number: 11027260
    Abstract: In embodiments a metal or metal alloy nanowires are assembled into a nanoporous membrane that can be used in methods for catalyzing various reactions under low pressures and achieving high flow rate of the reactions. In embodiments, the membranes of the disclosure can catalyze CuAAC reactions with high efficiency and minimum leaching of active Cu species.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 8, 2021
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Xiao-Min Lin, Jiangwei Wen, Kun Wu, Jun Tian
  • Patent number: 11026980
    Abstract: A flowable birth tissue composition fabricated from birth tissue is provided. Methods of processing a mammal's placental tissue to form a flowable birth tissue composition are provided. Various methods of treatment and uses are also provided.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: June 8, 2021
    Assignee: Triad Life Sciences, Inc.
    Inventors: Kurt Klitzke, Jon G. Hargis
  • Patent number: 11028360
    Abstract: The present invention provides a separator for microorganisms in cavitary contents. The separator for microorganisms in cavitary contents includes a raw material vessel, a stage filter, a liquid storage vessel, a closed separated material vessel, a separate loading unit, a deodorizer, pipelines for connecting all the units, etc.
    Type: Grant
    Filed: February 15, 2015
    Date of Patent: June 8, 2021
    Assignee: NANJING FMT MEDICAL CO., LTD.
    Inventors: Faming Zhang, Youquan Zhao, Huiquan Wang, Bota Cui, Pan Li, Guozhong Ji
  • Patent number: 11019817
    Abstract: Disclosed is a novel antimicrobial means which is effective against various types of fungi including pathogenic true fungi and phytopathogenic filamentous fungi. An antimicrobial agent against fungi according to the present invention comprises, as an effective ingredient, cyanoacrylate polymer particles having an average particle diameter of less than 1000 nm, which particles contain at least one selected from the group consisting of amino acids, amino acid derivatives, oligomers and polymers thereof, saccharides and polysorbates, and contain no antimicrobial active ingredient effective against the fungi. The antimicrobial agent is particularly useful as a control agent against plant diseases caused by filamentous fungi.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: June 1, 2021
    Inventor: Shoichi Shirotake
  • Patent number: 11013720
    Abstract: Disclosed herein is a ganetespib-containing particle, which includes an active ingredient selected from ganetespib, a pharmaceutically acceptable salt of ganetespib, and a combination thereof, and an amphiphilic chitosan-based carrier carrying the active ingredient. Also disclosed herein are a pharmaceutical composition including the ganetespib-containing particle, and use of such pharmaceutical composition in treating cancer.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 25, 2021
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Yan-Hwa Wu Lee, Dean-Mo Liu, Wei-Ting Huang, Ru-Tsun Mai, Yi-Hsin Chen
  • Patent number: 11013691
    Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: May 25, 2021
    Assignee: MannKind Corporation
    Inventors: Karine Fabio, Joseph J. Guarneri, Kieran Curley, Marshall L. Grant, Andrea Leone-Bay
  • Patent number: 11013899
    Abstract: Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 ?m to 1000 ?m deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 25, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Mohamed R. Ahmed, Jayakumar Rajadas, Wenchao Sun, Mohammed Inayathullah Nazir Ahmed, Feng Xu
  • Patent number: 11011603
    Abstract: Semiconductor nanocrystals prepared using a mixture of organic ligands (e.g., oxoacids), as well as compositions, kits, and methods of using such semiconductor nanocrystals are disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 18, 2021
    Assignee: Life Technologies Corporation
    Inventors: Joseph Bartel, Yongfen Chen, Noah Lermer, Timothy Carter, Scott Sweeney, Chad Teters, Wenxi Huang
  • Patent number: 11007203
    Abstract: Disclosed herein are oral dose formulations of aldosterone receptor antagonists, such as eplerenone and spironolactone, for the treatment of heart failure with preserved ejection fraction and uncontrolled hypertension.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: May 18, 2021
    Inventor: Salim Shah
  • Patent number: 11007201
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Patent number: 11000487
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 11, 2021
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11000543
    Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: May 11, 2021
    Assignee: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei Sun
  • Patent number: 10994085
    Abstract: An aerosol-generating system is provided, including an aerosol-generating device including a heater element, and an aerosol-generating article configured to engage with the aerosol-generating device. The aerosol-generating article includes a medicament source, a volatile delivery enhancing compound source, and at least one frangible barrier sealing the medicament source and the volatile delivery enhancing compound source. The aerosol-generating system also includes at least one piercing element disposed on one of the aerosol-generating device and the aerosol-generating article, the at least one piercing element being configured to pierce the at least one frangible barrier when activated by a user.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: May 4, 2021
    Assignee: Philip Morris Products S.A.
    Inventors: Jonathan Hogwood, Stuart Michael Ruan Jones, John Antony Stephenson, David Edington, Christopher Coulson
  • Patent number: 10993909
    Abstract: A composition and method for treating a mammal infected with a virus therein, and an inhalation delivery system for prevention and treatment of upper respiratory tract viruses, by administering a therapeutic dose of the composition to the mammal. The composition includes: microparticles and/or nanoparticles, wherein a pharmaceutically active agent, corticosteroid and/or hydroxychloroquine, niclosamide, and/or favipiravir, and a zinc salt are incorporated in the microparticles and/or nanoparticles. The pharmaceutically active agent is unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH), other glycosaminoglycans (GAGs), or combinations thereof.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 4, 2021
    Assignee: Virothera Pharmaceuticals LLC
    Inventor: Shaker A. Mousa
  • Patent number: 10988618
    Abstract: Novel, nano-structured particles are formed by introducing a selected solid of interest into a structured fluid matrix formed by a dispersion of a small molecule host vessel components, such as a native or modified polysaccharide, cavitand, simple sugar, disaccharide, simple polyol or other similarly structured molecule known to be useful as a host vessel, in an acidic medium or other solvent, whereby the particle size of the introduced solid is reduced and or limited in the structured fluid matrix, by incorporation into or attachment to, the host vessel. The simple, one-batch mixing process results in stabilized colloidal dispersions of the nanoparticles of a variety of solids of varying scope and function and useful in a wide variety of applications, including without limitation ceramic materials, such as hexagonal boron nitride.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: April 27, 2021
    Inventors: Gregory David Duncan, Jun Wang, Everett William Merling, Xiaoming Wu, James S. Brock, Kevin M. Henry, Joseph D. Kern
  • Patent number: 10987361
    Abstract: The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17?-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 27, 2021
    Assignee: Shenzhen Evergreen Therapeutics Co., Ltd.
    Inventors: Tao Tom Du, Chang Lee
  • Patent number: 10980762
    Abstract: The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: April 20, 2021
    Assignee: WINERGEN TECHNOLOGIES INC., LTD.
    Inventors: Zhongli Zheng, Wenyan Zhu
  • Patent number: 10973798
    Abstract: A dispersion of formononetin solid lipid nanoparticles and process for its preparation, namely having (i) a core system comprising formononetin, a lipid base, and a fluid medium, and (ii) an emulsifier system comprising an emulsifier, and water. The dispersion of formononetin solid lipid nanoparticles of the present disclosure can be used for treating cancer, osteoporosis, diabetes, and inflammation. The dispersion of formononetin solid lipid nanoparticles of the present disclosure are biocompatible, biodegradable, has improved solubility, has enhanced controlled drug release profile and are stable.
    Type: Grant
    Filed: December 23, 2018
    Date of Patent: April 13, 2021
    Assignee: SRM INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Karunanidhi Santhana Lakshmi, Vaithialingam Jagannathan Vishnu Varthan
  • Patent number: 10975206
    Abstract: A polar solvent solution of the present invention is a polar solvent solution in which a solute containing a polyamine acid is dissolved in a polar solvent. An inorganic salt is added to the solution, and a mole ratio of moisture to the inorganic salt in the solution is 2.5×m×n or less, where m represents the number of cations forming the inorganic salt and n represents a charge number of the cation. A production method of the present invention is a method for producing the above solution, including: changing at, least one of a moisture content and a content of the inorganic salt in the solution to adjust a viscosity of the solution. Thus, the present invention provides a polar solvent solution whose viscosity can be easily adjusted to a desired value and thus enables stable spinning and casting when used as dopes for spinning, film, etc., and methods for producing the same.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 13, 2021
    Assignee: SPIBER INC.
    Inventors: Kana Ishida, Hironori Yamamoto, Hiroaki Suzumura, Kazuhide Sekiyama
  • Patent number: 10967346
    Abstract: Provided is an organic solvent-free method for producing a plurality of microsphere having an average diameter of less than 500 ?m in diameter and having average contact angle ?c greater than 140°, consisting essentially of a biocompatible hot-melt carrier vehicle and a payload substance to be delivered, including melting and mixing a polymer carrier vehicle which is solid at room temperature and at least one payload substance, and dispensing microportions of the molten mixture through a droplet-forming space onto a cooled solid superoleophobic surface.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 6, 2021
    Assignee: Shenkar Engineering Design Art
    Inventors: Dan Lewitus, Tal Shpigel Shtauber
  • Patent number: 10971734
    Abstract: There is provided a planar structural body 1 comprising a fibrous carbon nanohorn aggregate 2 in which a plurality of single-walled carbon nanohorns are aggregated in a fibrous state, and particularly the planar structural body in which a globular carbon nanohorn aggregate 3 is mixed is used. The planar structural body comprising such a fibrous carbon nanohorn aggregate can be used for electrode materials for lithium ion batteries, fuel cells, capacitors, electrochemical actuators, air cells, solar cells, and the like, and can be used also for electromagnetic shields, thermoconductive sheets, heat-dissipating sheets, protecting sheets, filters and absorbing materials.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 6, 2021
    Assignee: NEC CORPORATION
    Inventor: Ryota Yuge
  • Patent number: 10959955
    Abstract: Two vial containing kits containing aspirin for intravenous administration are disclosed. The first vial contains a lyophilized mixture of aspirin in crystalline form, a bulking agent such as mannitol and a surfactant. The second vial includes an aqueous diluent such as water for injection and a basifying agent such as Tris.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 30, 2021
    Assignee: RHOSHAN PHARMACEUTICALS, INC.
    Inventor: Nagesh R. Palepu
  • Patent number: 10960010
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: March 30, 2021
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
  • Patent number: 10959958
    Abstract: The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: March 30, 2021
    Assignee: Pharmaceutical Manufacturing Research Services, Inc.
    Inventors: Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny, Matthew N. Hart
  • Patent number: 10953085
    Abstract: Genetically engineered Foot and Mouth Disease Virus (FMDV) and related engineered proteins and polynucleotides, nanolipoprotein particles, compositions, methods and systems are described. The genetically engineered FMDV is modified by the strategic insertion of a protein tag into select regions of the FMDV genome which encode viral proteins that are exposed on the surface of the FMDV viral capsid. The inserted protein tag is displayed as a decoration or attachment on the viral capsid surface.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: March 23, 2021
    Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE, THE UNIVERSITY OF CONNECTICUT
    Inventors: Aida E. Rieder, Teresa B. De Los Santos, Luis L. Rodriguez, Devendra Rai, Fayna C. Diaz-San Segundo, Paul D. Hoeprich
  • Patent number: 10946029
    Abstract: Compositions comprising a corticosteroid and a beta-adrenergic are useful for treating inflammatory or obstructive airways diseases.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 16, 2021
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Elisa Monari, Anna Maria Cantarelli, Daniela Cocconi, Irene Pasquali
  • Patent number: 10945974
    Abstract: Methods of weight management for a subject are provided. Generally the methods comprising: administering an effective amount to the small intestine and/or large intestine of the subject of at least one agent that increases oxygen tension and/or redox potential and/or pH in the colon of the subject to thereby manage the weight of the subject. Also provided are compositions comprising at least one agent that increases oxygen tension and/or redox potential and/or pH, wherein the composition is formulated for delivery of an effective amount of the at least one agent to the small intestine and/or large intestine of a subject following oral ad ministration of the composition to the subject.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: March 16, 2021
    Assignee: Xeno Biosciences Inc.
    Inventor: Hasan Celiker
  • Patent number: 10945846
    Abstract: An implant for the repair of bone and cartilage that includes a cell conductive zone that contains biopolymeric fibers and an osteoconductive zone that contains biopolymeric fibers and calcium-containing mineral particles. The biopolymeric fibers from one zone overlap with the fibers in the other zone forming a stable physical and mechanical integration of the two zones, thus conferring in vivo stability to the implant.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: March 16, 2021
    Assignee: Collagen Matrix, Inc.
    Inventors: Shu-Tung Li, Hui-Chen Chen, Debbie Yuen
  • Patent number: 10939949
    Abstract: Example methods and apparatuses are disclosed for providing tissue ablation through electrolysis, electroporation, or a combination thereof. A way to deliver the combination through a pulse that has an element of gradual decay and can thereby reduce both muscle contraction and electric breakdown discharge at the electrodes is disclosed. The apparatus disclosed may include an electrode, a power supply, and a controller. The controller may control a charge applied to the electrode to induce a direct current through a treatment site to produce electrolysis products and a voltage to produce electroporation. The duration and magnitude of the charge applied may determine the dose of the products and the degree of the permeabilization of cells in the treatment site.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 9, 2021
    Assignees: INTER SCIENCE GMBH, RM2 TECHNOLOGY LLC
    Inventors: Boris Rubinsky, Paul Mikus, Liel Rubinsky, Michael Klaus Stehling, Enric Günther
  • Patent number: 10940163
    Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 9, 2021
    Assignee: McMaster University
    Inventors: Eric Brown, Maya Farha, Craig MacNair, Jonathan Stokes
  • Patent number: 10933061
    Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 2, 2021
    Assignee: Shepherd Therapeutics, Inc.
    Inventors: Katherine Arline, Jamie Dempsey Barber, William M. Siders, Johanne Kaplan
  • Patent number: 10933025
    Abstract: The present invention relates to nanoparticles for encapsulating biologically active compounds, comprising a matrix of new polymer conjugates. The invention also relates to a process for producing both the conjugates and nanoparticles, to compositions containing said conjugates or nanoparticles, and applications thereof. The invention is applicable in the pharmaceutical sector and in the nanotechnology sector.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 2, 2021
    Assignee: INNOUP FARMA, S.L.
    Inventors: Juan Manuel Irache Garreta, Judit Huarte Ciganda, Laura Inchaurraga Casadamón, Luisa Fernanda Ruiz Gatón, Nekane Martín Arbellá
  • Patent number: 10925871
    Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: February 23, 2021
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Brij Khera, Muthaiyyan Essakimuthu Kannan, Jitendra Rameshchandra Patel, Saurin Mukundbhai Amin
  • Patent number: 10918602
    Abstract: The present disclosure provides improved film based pharmaceutical products containing uniformly distributed drug or active agent particles (e.g., to achieve improved/excellent dissolution control including enhancing dissolution and bioavailability and/or product uniformity). More particularly, the present disclosure provides improved systems/methods for fabricating film based pharmaceutical products by utilizing higher surface modified micronized drug or active agent powders and film forming precursors and drying methods that accomplish improved/efficient drying and provide improved/excellent content uniformity of active pharmaceutical agents in the fabricated film based pharmaceutical products. In exemplary embodiments, the present disclosure provides for an easier means of directly incorporating dry micronized poorly water-soluble drugs or active agent particles (e.g., fenofibrate (“FNB”)) into films.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: February 16, 2021
    Assignee: New Jersey Institute of Technology
    Inventors: Rajesh N. Dave, Lu Zhang, Guluzar Gorkem Buyukgoz, Eylul Cetindag
  • Patent number: 10920177
    Abstract: The present invention relates to compositions of benefit agent containing delivery particles and slurries comprising benefit agent containing delivery particles, compositions comprising the particles, and processes for making and using the aforementioned particles and compositions. Such slurries and benefit agent containing delivery particles are stable and when employed in compositions, for example, cleaning or fabric care compositions, the particles in such slurries increase the efficiency of benefit agent delivery, thereby allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. The compositions can comprise particles, cakes, powders, particulates, aggregates, aggregate clusters and slurries comprising the benefit agent containing delivery particles.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 16, 2021
    Inventors: Johan Smets, Corey James Kenneally, Ariel Lebron, Pascale Claire Annick Vansteenwinckel, Robert Stanley Bobnock, Peggy Dorothy Sands, Todd Arlin Schwantes, Chad Alexander Hladilek
  • Patent number: 10905695
    Abstract: The present invention relates to an ophthalmic composition for lowering an intraocular pressure, the composition comprising latanoprost, polyoxyl 40 hydrogenated castor oil, and sorbitol.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: February 2, 2021
    Assignee: TAEJOON PHARMACEUTICAL CO., LTD.
    Inventors: Joon Youb Lee, Youn Jae Shin, Min Ji Lee
  • Patent number: 10905660
    Abstract: The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: February 2, 2021
    Assignee: NOVABIOTICS LIMITED
    Inventor: Deborah O'Neil
  • Patent number: 10894025
    Abstract: Compositions comprising the nitrate of arginine are disclosed. In some aspects, the nitrate of arginine is a salt of a nitric acid (NO3?) or a mixed salt of a nitric acid (NO3?). The compositions further comprise one or more additional components selected from the group consisting of a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, and a dilutant. In one aspects, the composition is in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, and a lozenge. In other aspects, the composition is for human ingestion. In some embodiments, the composition, for example the composition for human ingestion, is a human dietary supplement.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 19, 2021
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Alexandros Nikolaidis, Ronald Kramer
  • Patent number: 10881720
    Abstract: The invention relates, in part, to nanoparticles, methods for preparing nanoparticles and methods of administering nanoparticles for immune stimulation. An immune-stimulating nanoparticle of the invention may include, at least in part, a polymer substrate comprising a biodegradable polymer and may include at least one antigen and/or at least one adjuvant.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: January 5, 2021
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, RENSSELAER POLYTECHNIC INSTITUTE
    Inventors: Elizabeth Leadbetter, Eyal Amiel, Emilie Vomhof-Dekrey, Robert Lindhardt, Amanda MacDonald, Jianjun Maio
  • Patent number: 10869885
    Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: December 22, 2020
    Assignee: Orbis Health Solutions LLC
    Inventor: Thomas E. Wagner
  • Patent number: 10856559
    Abstract: The method of producing eggshell-derived nanoparticles may include steps of adding eggshell powder to methanol to form a solution; adding the solution dropwise to boiling water under ultrasonic conditions; incubating the resulting solution under continuous stirring at 200-800 rpm; and drying the resulting solution to obtain the eggshell-derived nanoparticles. The method produces nanoparticles of between 5 and 100 nm. Cytotoxicity testing shows that the nanoparticles exhibit anticancer activity against human breast cancer and lung cancer cell lines.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: December 8, 2020
    Assignee: KING SAUD UNIVERSITY
    Inventors: Khalid Mustafa Osman Ortashi, Manal Ahmed Gasmelseed Awad, Awatif Ahmed Hendi
  • Patent number: 10850212
    Abstract: A process for purifying an extracted material extracted from a biomass material, providing a raw extracted material comprising an amount of a solvent or an extractable compound, heating the raw extracted material to a temperature sufficient to provide and maintain a flowable form, and to raise the partial pressure of the solvent or the extractable compound, increasing the surface area of the raw extracted material, passing a purifying gas across the increased surface area of the raw extracted material, to remove solvent and the extractable compound into the purifying gas to produce a stripped extract material, exposing the stripped extract material to a vacuum pressure to remove residual purifying gas, solvent, and the extractable compound to produce a first-stage purified extract material, and repeating one or more times to prepare a purified extract material.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: December 1, 2020
    Inventors: Michael Cem Gokay, Kaan Brian Gokay
  • Patent number: 10849908
    Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 1, 2020
    Assignee: SPRUCE BIOSCIENCES, INC.
    Inventors: Alexis Howerton, Hal Gerber, Michael Huang
  • Patent number: 10842794
    Abstract: Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 24, 2020
    Assignees: Támogatott Kutatócsoportok Irodája, Semmelweis Egyetem, SigmaDrugs Kft.
    Inventors: Andrea Fekete, Ádám Vannay, Endre Illés Kovács